I find it very interesting in reading the article of "In-Depth Evaluation of the AJCC 2010 Staging System for Luminal-like Breast Cancer-An Analysis from a Free-Standing Cancer Hospital." by Cheng, Skye HC, et al. [1] Prior to the era of molecular biology age, anatomically-based TNM staging system is the only and the best parameter of the prognostic value in the field of management of the solid tumor. To use biological nature to exam and to correlate to the anatomic abnormalities may not always be resulted in sound conclusion yet it may bring up some important questions of different aspects between biology and anatomy [2] .
The primary tumor size used in figure 2 and the five-year BCSR of three different groups (T,N) in table 3 were different from those data in AJCC, 7 th edition, 2010 [2] . Thus, it would be very difficult for us to compare between them and subsequently to draw any reasonable definitive conclusions.
There was no mention of the terminology of "Luminal" in St. Gallen Consensus Conference until "Luminal A and Luminal B" in 2011 [3] and "Luminal A-like and Luminal B-like" as clinico-pathologic sur-rogate definition in 2013 [4] . In terms of the types of therapy for Luminal A-like, the conclusive statement is as follow : "Endocrine therapy is the most critical intervention and is often used alone. Cytotoxics may be added in selected patients.……." [3, 4] . However, this is quite contrary to the view expressed in the section of the discussion of the article [1] .
Although the current TNM anatomically-based staging system is not perfect yet the questions of 1.
Does biology matter and 2. Can it trump anatomy?
remained to be answered [5] . For these critical important issues we may need more data available to us in order to be able to delineate further in the near future.
